Comparative Bioavailability of Methylphenidate Powder for Prolonged-Release Oral Suspension and Methylphenidate Prolonged-Release Chewable Tablets versus Methylphenidate Immediate-Release Tablets: Phase 1, Single-Dose, Randomised, Crossover Studies i

The methylphenidate PR oral suspension and chewable tablet formulations are bioequivalent in terms of the total extent of exposure (AUC<sub>last</sub>) to methylphenidate IR tablets and are tolerable in healthy adults.

Authors

Institutions

Publication Details

Journal
Clinical Drug Investigation
Published
2025-10-15
DOI
https://doi.org/10.1007/s40261-025-01474-3
Primary Topic
Attention Deficit Hyperactivity Disorder
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Comparative Bioavailability of Methylphenidate Powder for Prolonged-Release Oral Suspension and Methylphenidate Prolonged-Release Chewable Tablets versus Methylphenidate Immediate-Release Tablets: Phase 1, Single-Dose, Randomised, Crossover Studies i

Josep Antoni Ramos‐Quiroga, Mohammed Bouhajib, Marta Forcadell Ferré, Alex Schneider-Pérez
Clinical Drug Investigation
Attention Deficit Hyperactivity Disorder
article

Comparative Bioavailability of Methylphenidate Powder for Prolonged-Release Oral Suspension and Methylphenidate Prolonged-Release Chewable Tablets versus Methylphenidate Immediate-Release Tablets: Phase 1, Single-Dose, Randomised, Crossover Studies i

Josep Antoni Ramos‐Quiroga, Mohammed Bouhajib, Marta Forcadell Ferré, Alex Schneider-Pérez
article en

Abstract

The methylphenidate PR oral suspension and chewable tablet formulations are bioequivalent in terms of the total extent of exposure (AUC<sub>last</sub>) to methylphenidate IR tablets and are tolerable in healthy adults.

Clinical Drug InvestigationVol. 45(12)
Universitat Autònoma de Barcelona (ES), Centro de Investigación Biomédica en Red de Salud Mental (ES), Vall d'Hebron Institut de Recerca (ES), Neuraxpharm (Spain) (ES), Centre for Biomedical Network Research on Rare Diseases (ES), Vall d'Hebron Hospital Universitari (ES), Pharma Medica Research (Canada) (CA)
Neuraxpharm
Openalex Percentile: Top 65%
Attention Deficit Hyperactivity Disorder
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Comparative Bioavailability of Methylphenidate Powder for Prolonged-Release Oral Suspension and Methylphenidate Prolonged-Release Chewable Tablets versus Methylphenidate Immediate-Release Tablets: Phase 1, Single-Dose, Randomised, Crossover Studies i — Josep Antoni Ramos‐Quiroga, Mohammed Bouhajib, et al. · Clinical Drug Investigation (2025) | TGRS Research Map | TGRS